摘要
Intratumoral pathogenic bacteria influence tumor progression and affect responses to therapy, however, conventional antibacterial strategies face challenges including antibiotic resistance and nonspecific microbial disruption. Here, we report a NIR-II-responsive nanoplatform (VP-R@PEG-FA) that integrates violet phosphorus nanosheets (VPNSs) with the Toll-like receptor 7 (TLR7) agonist imiquimod (R837) and folate targeting for synergistic photothermal immunotherapy. Under 1064 nm laser irradiation, VP-R@PEG-FA generates localized hyperthermia that simultaneously eradicates tumor cells and intratumoral bacteria. This dual ablation strategy not only eliminates intratumoral pathogenic bacteria but also ingeniously converts them into in situ immunoadjuvants, as bacterial debris releases pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) which acts as an endogenous TLR4 agonist. The combination of bacterially derived TLR4 ligands and nanoparticle-delivered TLR7 agonist R837 induces potent combined immune activation, driving robust maturation of dendritic cells (DCs) and increasing CD8⁺ T cell infiltration. In 4T1 Triple-negative Breast Cancer (TNBC) models, this approach demonstrates significant primary tumor suppression and, notably, elicits abscopal effects in bilateral tumor models, indicating the enhanced systemic antitumor immunity. This work presents a “waste-to-wealth” strategy that repurposes intratumoral bacteria from immunosuppressive agents into immunostimulants, offering a promising strategy for advancing cancer immunotherapy through rational manipulation of the tumor microenvironment.
危险品化学品经营许可证(带存储)